CKD-510 / Chong Kun Dang, Novartis - LARVOL DELTA

Chong Kun Dang licenses out HDAC6 inhibitor CKD-510 to Novartis for $1.3 billion (Korea Biomedical Review) - "Chong Kun Dang Pharmaceutical...said it has signed a $1.3 billion deal with global pharmaceutical giant Novartis to license out a new drug candidate, CKD-510....CKD Pharm said Monday in a public filing that it has signed a technology export contract worth $1.305 billion (about 1.73 trillion won) with Novartis Pharma AG, a global pharma based in Switzerland, for its new drug candidate, CKD-510. Under the agreement, Novartis will have global exclusive rights to develop and commercialize CKD-510, a small molecule histone deacetylase 6 (HDAC6) inhibitor developed by CKD Pharm worldwide, excluding Korea. The termination date will be the royalty expiration date from the date of signing the contract and be based on the later of 10 years after the first release, the patent expiration date, or the expiration of the licensee's exclusive rights."

Licensing / partnership • CNS Disorders • Rare Diseases

A Study to Evaluate the Relative Bioavailability of Formulations of CKD-510 and to Assess the Effect of Food on the CKD-510 Tablet Formulation in Healthy Subjects (clinicaltrials.gov) - P1 | N=16 | Completed | Sponsor: Chong Kun Dang Pharmaceutical | Recruiting ➔ Completed

Trial completion

A Randomized, Open-Label, Crossover Study to Evaluate the Relative Bioavailability of a Tablet Formulation of CKD-510 as Compared to Capsule and to Assess the Effect of Food on the CKD 510 Tablet Formulation in Healthy Subjects (clinicaltrials.gov) - P1 | N=16 | Recruiting | Sponsor: Chong Kun Dang Pharmaceutical

New P1 trial

Evaluation of the Safety and Tolerability of CKD-510 in Healthy Subjects (clinicaltrials.gov) - P1 | N=87 | Completed | Sponsor: Chong Kun Dang Pharmaceutical | Active, not recruiting ➔ Completed

Trial completion

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CKD-510 in Healthy Subjects (clinicaltrials.gov) - P1; N=88; Active, not recruiting; Sponsor: Chong Kun Dang Pharmaceutical

Clinical • New P1 trial